Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 321 followers
Latest posts
Last updated 2 days ago
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
2 days ago
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy...
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
4 days ago
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets...
Invitation to Roche’s 3rd Quarter Sales 2024 Presentation
5 days ago
Roche will publish its Sales for the 3rd Quarter of 2024 prior...
Reminder: Invitation to Roche’s Pharma Day 2024
9 days ago
The Roche Investor Relations team would like to invite you to the...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
9 days ago
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
12 days ago
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
15 days ago
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options...
Reminder: Invitation to Roche’s Virtual Investor Event at EASD
22 days ago
We are pleased to invite investors and analysts to participate in our...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
24 days ago
New Phase II data show vast majority of patients experiencing no relapses...
Invitation to Roche’s Pharma Day 2024
29 days ago
The Roche Investor Relations team would like to invite you to the...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
about 1 month ago
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce...
Invitation to Roche’s Virtual Investor Event at EASD
about 1 month ago
We are pleased to invite investors and analysts to participate in our...